Cargando…
Favipiravir exposure and pregnancy outcome of COVID-19 patients
OBJECTIVE: COVID-19 is a rapidly spreading disease and many people have been infected in a short time. Favipiravir is under investigation for the treatment of COVID-19 and given to patients in many countries following emergency use approval. Based on data from animal studies, favipiravir use is cont...
Autor principal: | Tırmıkçıoğlu, Zeynep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647391/ https://www.ncbi.nlm.nih.gov/pubmed/34902747 http://dx.doi.org/10.1016/j.ejogrb.2021.12.001 |
Ejemplares similares
-
The outcomes of favipiravir exposure in pregnancy: a case series
por: Ertem, Ozge, et al.
Publicado: (2022) -
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021) -
Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023) -
Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021) -
Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)